logo-loader
RNS
Advanced Oncotherapy PLC

Advanced Oncotherapy - Further update on financing discussions

RNS Number : 6128B
Advanced Oncotherapy PLC
01 February 2024
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

1 February 2024

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy", "AVO" or the "Company")

 

Further update on financing discussions

 

Further to the Company's announcement released on 9 January 2024, Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, provides the following update in relation to its financing discussions and financial position.

 

On 9 January 2024 the Company announced, inter alia, that it was continuing to work on its recapitalisation plan with the third-party investor (the "Investor") that it entered into a non-binding term sheet with on 14 November 2023 (the "Proposed Financing Transaction"). Discussions with the Investor on the Proposed Financing Transaction continue to make progress and the Investor has re-confirmed their continued commitment to the Proposed Financing Transaction. However, there have been some unexpected delays encountered with the Investor such that the initial tranche of funding has, as at the date of this announcement, not been received.

 

The Company and the Investor are now working towards the initial tranche of funding, which is expected to be in the region of $15 million, being received during February 2024. There can be no guarantee that this funding will be received nor the quantum or timing thereof.

 

As previously announced it is also expected that as part of the Proposed Financing Transaction the Company would be required to restructure its financial liabilities with a view to providing a long-term financing solution for the Company to continue as a going concern. The Proposed Financing Transaction would also be subject to, amongst other things, approval by shareholders of the Company and consent from certain other stakeholders of the Company.

 

Since the announcement made by the Company on 9 January 2024, the Company has been carefully managing its working capital position and its creditors. The Investor has made a CHF50,000 (equivalent to c. £45,000) advance payment on the Proposed Financing Transaction which has been put towards the Company's general working capital requirements. As at the date of this announcement, the Company has negligible cash resources and significant debt levels, as set out in the announcement of 9 January 2024.

 

The Company also remains in advanced discussions with a third-party investor regarding a short-term loan facility which, if put in place, would provide the Company with additional short term bridge financing while the Company progresses on the Proposed Financing Transaction.

 

Whilst the board of the Company is hopeful of a satisfactory outcome, there can be no certainty that the Proposed Financing Transaction will proceed nor that the short-term loan facility will be put in place. Without access to the additional capital which is proposed to be provided by the Investor pursuant to the Proposed Financing Transaction, the Company is unlikely to be able to continue to trade and would very likely become insolvent and be placed into administration.

 

Further to the Company's announcement of 9 January 2024 the Company's shares remain suspended from trading on AIM.

 

Further announcements will be made at the appropriate time.

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




WH Ireland Limited (Financial adviser)

Tel: +44 (0) 20 7220 1666

Antonio Bossi / James Bavister

AVOPLC@whirelandcm.com



Allenby Capital Limited (Nomad and Joint Broker)


Nick Athanas / Piers Shimwell (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Corporate Broking)

Tel: +44 (0) 20 3328 5656



SI Capital Ltd (Joint Broker)


Nick Emerson

Tel: +44 (0) 1483 413 500

Jon Levinson

Tel: +44 (0) 20 3871 4066



About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy Plc, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy Plc will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy Plc continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAFFFDFKLEAA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read